Quidel Corporation
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$1.6Mgeneral payments (2019-2025)
$520Kresearch payments (2019-2025)
1,642clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Kenneth Widder | Rancho Santa Fe, CA | Anatomic Pathology | $447,348.69 |
| Mary Polan | New York, NY | Obstetrics & Gynecology | $317,460.34 |
| Robert Sambursky | Bradenton, FL | Ophthalmology | $180,193.22 |
| Harald Jueppner | Boston, MA | Pediatrics | $104,179.76 |
| Paul Olivo | Saint Louis, MO | Internal Medicine | $56,375.29 |
| Stephen Gormican | La Jolla, CA | Emergency Medicine | $40,784.20 |
| Leanne Labriola | Urbana, IL | Ophthalmology | $31,553.73 |
| Lori Daniels | San Diego, CA | Cardiovascular Disease | $22,530.25 |
| Angela Caliendo | Providence, RI | Infectious Disease | $18,708.00 |
| Kamaljit Singh | Chicago, IL | Infectious Disease | $18,666.60 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.